American Headache Society 66th Annual Scientific Meeting June 13–16, 2024 San Diego, California

Abstract

ABHD6 partially reversed medication overuse headache induced allodynia induced by sumatriptan. Background : The pathophysiology of headache disorders such as medication overuse headache (MOH) is poorly understood, making treatment difficult. However, recent evidence has implicated the involvement of endocannabinoid deficiency, specifically in decreased levels of 2-AG within periaqueductal gray (PAG), in multiple models of headache pain. Our previous research has shown that blockade of 2-AG degradation using a selective ABHD6 inhibitor, KT-182, both prevented and reversed periorbital allodynia in a cortical spreading depression (CSD) headache model. Given our observations that MOH also reduced PAG levels of 2-AG, this study aimed to evaluate the efficacy of inhibiting ABHD6 for MOH headache like pain behaviors